This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
by Zacks Equity Research
PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.
Masimo (MASI) Introduces Automation and Connectivity Solution
by Zacks Equity Research
Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.
VREX vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. SRDX: Which Stock Is the Better Value Option?
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
by Zacks Equity Research
By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
NextGen Virtual Visits Offers Remote Eye Care Facilities
by Zacks Equity Research
The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.
LHC Group Inks Deal With Orlando Health to Improve HCBS
by Zacks Equity Research
This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.
Quidel (QDEL) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Surmodics (SRDX) Could Be Positioned for a Surge
by Zacks Equity Research
Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Ecolab's Unit Unveils Test Kit for Cooling Water Management
by Zacks Equity Research
Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.
Top Ranked Momentum Stocks to Buy for June 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 29th.
Top Ranked Momentum Stocks to Buy for June 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 26th
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
by Zacks Equity Research
Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
Here's Why You Should Retain Glaukos in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
by Zacks Equity Research
ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
Can SurModics (SRDX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.